Additionally, the TS-score showed stable performance in HR + HER2- breast cancer (AUC: PC 0.767, VC1 0.804, VC2 0.784, VC3 1.00), while the patch-level performance of the TS-score according to the three breast cancer subtypes is also shown in Fig. 3. This evidence concerns the gene ERBB2 and breast carcinoma.